Overview

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

Study PIM4973g is a multicenter, international, open-label Phase II trial. Participants with metastatic renal cell carcinoma who have progressed on or after VEGF targeted therapy will be randomized in 1:1 to two groups either to receive daily GDC-0980 or everolimus orally.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Endothelial Growth Factors
Everolimus
Sirolimus